000180837 001__ 180837
000180837 005__ 20240229145635.0
000180837 0247_ $$2doi$$a10.1016/S1470-2045(22)00222-4
000180837 0247_ $$2pmid$$apmid:35901835
000180837 0247_ $$2ISSN$$a1470-2045
000180837 0247_ $$2ISSN$$a1474-5488
000180837 0247_ $$2altmetric$$aaltmetric:133137125
000180837 037__ $$aDKFZ-2022-01586
000180837 041__ $$aEnglish
000180837 082__ $$a610
000180837 1001_ $$aLindsay, Holly B$$b0
000180837 245__ $$aResponse assessment in paediatric intracranial ependymoma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group.
000180837 260__ $$aLondon$$bThe Lancet Publ. Group$$c2022
000180837 3367_ $$2DRIVER$$aarticle
000180837 3367_ $$2DataCite$$aOutput Types/Journal article
000180837 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1662468096_21383$$xReview Article
000180837 3367_ $$2BibTeX$$aARTICLE
000180837 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000180837 3367_ $$00$$2EndNote$$aJournal Article
000180837 500__ $$a2022 Aug;23(8):e393-e401
000180837 520__ $$aResponse criteria for paediatric intracranial ependymoma vary historically and across different international cooperative groups. The Response Assessment in the Pediatric Neuro-Oncology (RAPNO) working group, consisting of an international panel of paediatric and adult neuro-oncologists, neuro-radiologists, radiation oncologists, and neurosurgeons, was established to address both the issues and the unique challenges in assessing the response in children with CNS tumours. We established a subcommittee to develop response assessment criteria for paediatric ependymoma. Current practice and literature were reviewed to identify major challenges in assessing the response of paediatric ependymoma to clinical trial therapy. For areas in which data were scarce or unavailable, consensus was reached through an iterative process. RAPNO response assessment recommendations include assessing disease response on the basis of changes in tumour volume, and using event-free survival as a study endpoint for patients entering clinical trials without bulky disease. Our recommendations for response assessment include the use of brain and spine MRI, cerebral spinal fluid cytology, neurological examination, and steroid use. Baseline postoperative imaging to assess for residual tumour should be obtained 24-48 h after surgery. Our consensus recommendations and response definitions should be prospectively validated in clinical trials.
000180837 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000180837 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000180837 7001_ $$aMassimino, Maura$$b1
000180837 7001_ $$aAvula, Shivaram$$b2
000180837 7001_ $$aStivaros, Stavros$$b3
000180837 7001_ $$aGrundy, Richard$$b4
000180837 7001_ $$aMetrock, Katie$$b5
000180837 7001_ $$aBhatia, Aashim$$b6
000180837 7001_ $$aFernández-Teijeiro, Ana$$b7
000180837 7001_ $$aChiapparini, Luisa$$b8
000180837 7001_ $$aBennett, Jeffrey$$b9
000180837 7001_ $$aWright, Karen$$b10
000180837 7001_ $$aHoffman, Lindsey M$$b11
000180837 7001_ $$aSmith, Amy$$b12
000180837 7001_ $$0P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aPajtler, Kristian$$b13$$udkfz
000180837 7001_ $$aPoussaint, Tina Young$$b14
000180837 7001_ $$aWarren, Katherine E$$b15
000180837 7001_ $$aForeman, Nicholas K$$b16
000180837 7001_ $$aMirsky, David M$$b17
000180837 773__ $$0PERI:(DE-600)2035574-9$$a10.1016/S1470-2045(22)00222-4$$gVol. 23, no. 8, p. e393 - e401$$n8$$pe393-e401$$tThe lancet <London> / Oncology$$v23$$x1470-2045$$y2022
000180837 909CO $$ooai:inrepo02.dkfz.de:180837$$pVDB
000180837 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000180837 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000180837 9141_ $$y2022
000180837 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-29
000180837 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-29
000180837 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-29
000180837 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-29
000180837 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-29
000180837 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-29
000180837 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-29
000180837 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLANCET ONCOL : 2021$$d2022-11-29
000180837 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-29
000180837 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-29
000180837 915__ $$0StatID:(DE-HGF)9950$$2StatID$$aIF >= 50$$bLANCET ONCOL : 2021$$d2022-11-29
000180837 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000180837 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000180837 980__ $$ajournal
000180837 980__ $$aVDB
000180837 980__ $$aI:(DE-He78)B062-20160331
000180837 980__ $$aI:(DE-He78)HD01-20160331
000180837 980__ $$aUNRESTRICTED